Birinyi Associates Raised Alibaba Group Holding LTD (BABA) Holding; Orient Paper (ORPN) Has 0.33 Sentiment

March 24, 2018 - By Hugh Holland

Birinyi Associates Inc increased Alibaba Group Holding Ltd (BABA) stake by 307.27% reported in 2017Q3 SEC filing. Birinyi Associates Inc acquired 8,450 shares as Alibaba Group Holding Ltd (BABA)’s stock rose 22.58%. The Birinyi Associates Inc holds 11,200 shares with $1.93 million value, up from 2,750 last quarter. Alibaba Group Holding Ltd now has $465.59B valuation. The stock decreased 1.87% or $3.45 during the last trading session, reaching $181.2. About 18.71M shares traded. Alibaba Group Holding Limited (NYSE:BABA) has risen 57.33% since March 24, 2017 and is uptrending. It has outperformed by 40.63% the S&P500.

Bioblast Pharma Ltd., a clinical-stage biotechnology company, focuses on the development of clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. The company has market cap of $7.72 million. It develops Trehalose 90mg/mL IV solution, a protein stabilizer and autophagy enhancer to treat patients with oculopharyngeal muscular dystrophy and spinocerebellar ataxia type 3. It currently has negative earnings.

Among 38 analysts covering Alibaba (NYSE:BABA), 36 have Buy rating, 1 Sell and 1 Hold. Therefore 95% are positive. Alibaba had 170 analyst reports since August 12, 2015 according to SRatingsIntel. The stock has “Buy” rating by Robert W. Baird on Thursday, June 22. Jefferies maintained it with “Buy” rating and $12200 target in Tuesday, June 6 report. The firm has “Buy” rating given on Friday, August 12 by Jefferies. The stock of Alibaba Group Holding Limited (NYSE:BABA) has “Overweight” rating given on Tuesday, August 22 by Atlantic Securities. On Friday, August 12 the stock rating was maintained by Credit Suisse with “Outperform”. The company was maintained on Friday, February 2 by KeyBanc Capital Markets. The firm earned “Buy” rating on Thursday, March 24 by Deutsche Bank. On Thursday, January 21 the stock rating was upgraded by Standpoint Research to “Buy”. The firm earned “Overweight” rating on Wednesday, October 28 by Morgan Stanley. On Tuesday, March 6 the stock rating was maintained by Oppenheimer with “Buy”.

Birinyi Associates Inc decreased Nvidia Corp (NASDAQ:NVDA) stake by 3,000 shares to 7,600 valued at $1.36 million in 2017Q3. It also reduced American Airlines Group Inc (NASDAQ:AAL) stake by 10,750 shares and now owns 23,000 shares. Guggenheim S&P 500 Equal Weight Etf (RSP) was reduced too.

Blackrock Inc. holds 0% of its portfolio in Bioblast Pharma Ltd. for 152,906 shares. Bridgeway Capital Management Inc owns 163,811 shares or 0% of their US portfolio. Moreover, California Public Employees Retirement System has 0% invested in the company for 35,200 shares. The Germany-based Deutsche Bank Ag has invested 0% in the stock. Renaissance Technologies Llc, a New York-based fund reported 82,300 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News